Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Asparaginase and Pembrolizumab in Nasopharyngeal Carcinoma
NCT06676293Completed
- Sponsor
- Chang Gung Memorial Hospital
- Start
- Aug 2023
- Primary completion
- Apr 2024
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of asparaginase escherichia coli in nasopharyngeal carcinoma (NPC) (2 arms), sponsored by Chang Gung Memorial Hospital. Primary endpoint: Quantitative Analysis of Plasma EBV DNA Levels for Treatment Response. Started Aug 2023; status: completed.
02
Drugs
asparaginase escherichia coli
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT06676293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06676293.